Skip to main content

Palvella Therapeutics, Inc.

corporate_fare Company Profile

Palvella Therapeutics, Inc.

PVLA·NASDAQ·Life Sciences·CIK 0001583648

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations that currently lack FDA-approved treatments. On December 13, 2024, the company completed a business combination with Legacy Palvella, resulting in Legacy Palvella becoming a wholly-owned subsidiary and the company changing its name from Pieris Pharmaceuticals, Inc. to Palvella Therapeutics, Inc. Its business is now primarily that of Legacy Palvella. The company aims to become a leader in rare disease biopharmaceuticals by providing improved treatment options that address the underlying causes of these conditions. Palvella leverages its QTORIN platform, designed to generate novel topical product candidates that penetrate deep skin layers for local treatment of a broad range of rare skin diseases and vascular malformations. The company's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations.

Palvella Therapeutics, Inc. (NASDAQ:PVLA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 36 items for PVLA at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Palvella Therapeutics Doses First Patients in Phase 2 Lotu Trial for Fast Track-Designated Qtorin™ Rapamycin
  • Palvella Therapeutics Details Accelerated Pipeline, Key Regulatory Milestones, and Commercial Readiness
  • Palvella Therapeutics Reports FY2025 Results, Highlights Positive Phase 3 Data & $215.8M Public Offering
  • Palvella Therapeutics Reports Strong Clinical Progress and $230M Financing, Bolstering Pipeline and Launch Readiness
  • Palvella Therapeutics Reports $3.71 Per Share Loss for 2025

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$41.72M
Diluted EPS
-$3.71
Op. Cash Flow
-$25.01M
Operating Income
-$38.6M
Cash & Equivalents
$57.98M
Debt / Equity
0.00×
Shares Outstanding
12.38M sh
Source: 10-K · filed 2026-03-31 · accession 0001193125-26-133372
$142.85
52-week range · as of 2026-11-19 $72.22 – $179.95
Market cap
$2.09B
Volume
192.7K (0.7× avg)
3-mo avg 263.6K
Live data · 2026-11-22 12:55 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed PVLA - Filings & News (Page 2)

PVLA
May 04, 2026, 7:36 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $125.60
Real-time Price: $142.85 info
Change: +$17.25 (+14%) info
Market Cap: $2.088B info
PVLA
Apr 07, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $120.45
Real-time Price: $142.85 info
Change: +$22.40 (+19%) info
Market Cap: $2.088B info
PVLA
Mar 31, 2026, 8:30 AM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $110.66
Real-time Price: $142.85 info
Change: +$32.19 (+29%) info
Market Cap: $2.088B info
PVLA
Mar 31, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $110.66
Real-time Price: $142.85 info
Change: +$32.19 (+29%) info
Market Cap: $2.088B info
PVLA
Mar 31, 2026, 7:32 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $110.66
Real-time Price: $142.85 info
Change: +$32.19 (+29%) info
Market Cap: $2.088B info
PVLA
Mar 30, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $112.40
Real-time Price: $142.85 info
Change: +$30.45 (+27%) info
Market Cap: $2.088B info
PVLA
Mar 27, 2026, 10:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $115.48
Real-time Price: $142.85 info
Change: +$27.37 (+24%) info
Market Cap: $2.088B info
PVLA
Mar 23, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $112.50
Real-time Price: $142.85 info
Change: +$30.35 (+27%) info
Market Cap: $2.088B info
PVLA
Feb 26, 2026, 5:33 PM EST
Source: Unknown
Importance Score:
8
Price at Filing: $150.98
Real-time Price: $142.85 info
Change: -$8.13 (-5%) info
Market Cap: $2.088B info
PVLA
Feb 26, 2026, 5:31 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $150.98
Real-time Price: $142.85 info
Change: -$8.13 (-5%) info
Market Cap: $2.088B info
PVLA
Feb 24, 2026, 4:27 PM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $118.77
Real-time Price: $142.85 info
Change: +$24.08 (+20%) info
Market Cap: $2.088B info
PVLA
Feb 24, 2026, 4:23 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $118.77
Real-time Price: $142.85 info
Change: +$24.08 (+20%) info
Market Cap: $2.088B info
PVLA
Feb 24, 2026, 6:30 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $98.99
Real-time Price: $142.85 info
Change: +$43.86 (+44%) info
Market Cap: $2.088B info
PVLA
Jan 29, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $81.90
Real-time Price: $142.85 info
Change: +$60.95 (+74%) info
Market Cap: $2.088B info
PVLA
Jan 12, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $94.00
Real-time Price: $142.85 info
Change: +$48.85 (+52%) info
Market Cap: $2.088B info
PVLA
Jan 02, 2026, 8:02 AM EST
Filing Type: S-3
Importance Score:
8
Price at Filing: $104.67
Real-time Price: $142.85 info
Change: +$38.18 (+36%) info
Market Cap: $2.088B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets